Pirtobrutinib
VIDEO: Can mantle cell lymphoma be cured? Expert explores next steps
In this video, Stephen M. Ansell, MD, PhD professor of medicine, chair of the division of hematology, co-leader of the hematological malignancies program, and interim chair of the department of oncology at Mayo Clinic, discusses recent advancements in the treatment and study of mantle cell lymphoma.
VIDEO: BTK inhibitors may reduce need for intensive induction therapy in mantle cell lymphoma
In this video, Stephen M. Ansell, MD, PhD professor of medicine, chair of the division of hematology, co-leader of the hematological malignancies program, and interim chair of the department of oncology at Mayo Clinic, discusses recent advancements in the treatment and study of mantle cell lymphoma.
VIDEO: CAR T-cell therapy shows promise in hard-to-treat mantle cell lymphoma
In this video, Stephen M. Ansell, MD, PhD professor of medicine, chair of the division of hematology, co-leader of the hematological malignancies program, and interim chair of the department of oncology at Mayo Clinic, discusses recent advancements in the treatment and study of mantle cell lymphoma.
VIDEO: Immunotherapies, BTK inhibitors transforming mantle cell lymphoma field
In this video, Stephen M. Ansell, MD, PhD professor of medicine, chair of the division of hematology, co-leader of the hematological malignancies program, and interim chair of the department of oncology at Mayo Clinic, discusses recent advancements in the treatment and study of mantle cell lymphoma.
VIDEO: Advances improve accuracy of mantle cell lymphoma diagnosis
In this video, Stephen M. Ansell, MD, PhD professor of medicine, chair of the division of hematology, co-leader of the hematological malignancies program, and interim chair of the department of oncology at Mayo Clinic, discusses recent advancements in the treatment and study of mantle cell lymphoma.
VIDEO: Pirtobrutinib ‘superior’ for relapsed CLL
SAN DIEGO — In this video, Jennifer A. Woyach, MD, discusses a phase 3 randomized trial comparing pirtobrutinib to idelalisib or bendamustine plus rituximab for chronic lymphocytic leukemia pretreated with Bruton tyrosine kinase inhibitor.
First-line regimen improves PFS in chronic lymphocytic leukemia
SAN DIEGO — A multidrug combination significantly improved survival for certain patients with leukemia compared with standard chemoimmunotherapy, according to results of the randomized phase 3 AMPLIFY study.
VIDEO: AI, big data may transform CLL treatment, prognosis
In a video interview, Matthew Cortese, MD, MPH, discusses how AI could transform the treatment landscape for CLL.
VIDEO: ‘Mutual trust’ in long-term monitoring for patients with CLL
In a video interview, Matthew Cortese, MD, MPH, discusses the importance of long-term monitoring in CLL care.
VIDEO: Expert discusses strategies to combat infections in patients with CLL
In a video interview, Matthew Cortese, MD, MPH, discusses strategies to combat infections in CLL patients.